The Canadian prescription options differ in ways that matter once you have to use one regularly. The hormone and dose are part of the choice, along with how you apply it, what its label says and what your drug plan will cover.
When sex hurts or burning keeps returning, the particulars of a prescription start to matter. If your skin already stings, what’s in the cream base? If an applicator is awkward to use, is there a form you would find easier? The answers can help you compare products with a clinician or pharmacist, alongside the question of insurance coverage.
This comparison focuses on Canadian products rather than repeating the full explanation of genitourinary syndrome of menopause, or GSM. For symptoms, examination and other treatment options, start with our comprehensive GSM guide. A diagnosis matters: persistent burning, discharge, sores or vulvar skin changes can have causes that estrogen alone will not treat.
IN THIS ARTICLE
- Local treatment has a different job from systemic HRT
- Canadian vaginal-estrogen products compared
- Cream, insert or ring: what is likely to fit your life?
- Do you need progesterone with vaginal estrogen?
- Absorption, breast cancer and long-term use
- What does it cost in Canada?
- What if the pharmacy cannot obtain it—or it does not help?
- Sources and product information
Local treatment has a different job from systemic HRT
Low-dose vaginal estrogen acts mainly on tissues in and around the vagina and lower urinary tract. It can improve dryness and painful intercourse associated with GSM; vaginal estrogen is also recommended in appropriate peri- and postmenopausal patients to reduce recurrent urinary tract infections. It does not replace antibiotics when an infection requires them. Symptoms such as urgency or burning can overlap with infection, overactive bladder and other conditions, so a prescription should follow an appropriate assessment.
These local preparations are not intended to treat hot flashes or protect bones. Conversely, systemic estrogen does not always relieve vaginal symptoms sufficiently, and some people use local treatment alongside their usual HRT. That combination should be reviewed as a whole. Our Canadian MHT guide explains systemic therapy, while UTI symptoms with negative tests explains why repeated urinary discomfort should not automatically mean another antibiotic.
Canadian vaginal-estrogen products compared
The products below have Canadian marketed listings or current Canadian manufacturer prescribing information checked for this review. A marketed listing does not guarantee local pharmacy stock. These are prescription examples, not instructions to start or change treatment. Follow the directions on your own prescription and ask about discrepancies between those directions and the package leaflet.
On a phone, swipe across the comparison table.
| Product | Hormone and strength | Route and label regimen | Practical distinction |
|---|---|---|---|
| Vagifem 10 | Estradiol, 10 micrograms per vaginal insert | Vaginal: one insert daily for two weeks, then one twice weekly, with 3–4 days between doses. | Each insert comes preloaded in an applicator. A measured dose with less cream residue. |
| Imvexxy | Estradiol, 4 or 10 micrograms per softgel insert | Vaginal: one daily for two weeks, then one twice weekly, 3–4 days apart. Canadian label generally starts at 4 micrograms, with adjustment by response. | Inserted by hand without an applicator. Not an oral capsule. |
| Estring | Estradiol: 2 mg reservoir releasing about 7.5 micrograms daily | Vaginal ring left in place continuously and replaced every 90 days. | Less frequent administration; fitting, insertion and removal still matter. The reservoir amount is not a daily dose. |
| Premarin Vaginal Cream | Conjugated estrogens, 0.625 mg per gram | Vaginal/topical: Canadian label includes a low-dose 0.5 g twice-weekly regimen and a separate cyclic daily regimen. Use the prescribed amount and schedule. | A measured cream dose allows application flexibility. Contains a mixture of conjugated estrogens, not estradiol alone. |
| Estragyn Vaginal Cream | Estrone, 0.1% w/w (1 mg per gram) | Vaginal: manufacturer monograph describes 0.5–4 g daily, adjusted to the lowest effective amount, for short-term cyclic use, for example three weeks on and one off. | Not equivalent to US 0.01% estradiol cream. Label and endometrial-protection cautions need particular attention. |
Micrograms, milligrams and grams describe different things here. Grams on a cream applicator measure the amount of cream, not the amount of pure estrogen. Even matching the number of milligrams would not make estrone, estradiol and conjugated estrogens equivalent. Do not transfer a dose from a US product, an online photograph or another person’s prescription to your own tube.
Cream, insert or ring: what is likely to fit your life?
A cream can be useful when a clinician wants to treat external vulvar symptoms as well as vaginal symptoms. It can also involve leakage, applicator cleaning or irritation from the formulation. Premarin’s Canadian formulation includes fragrance; Estragyn is marketed as fragrance-free. Neither fact predicts your individual response. Ask a pharmacist to review inactive ingredients if a product burns, rather than concluding that you cannot tolerate any estrogen. Persistent or severe irritation warrants examination.
Vagifem offers a premeasured dose with a disposable applicator. Imvexxy removes the applicator step, which may be welcome for one person and awkward for another with limited reach or dexterity. Neither formulation should be forced into painful tissue. Ask for a demonstration or an alternative if insertion is difficult; do not split inserts, dissolve them in improvised mixtures or add extra doses because you notice residue.
Estring may appeal if remembering twice-weekly treatment is difficult. It is a local estrogen ring, not a contraceptive ring, a systemic estrogen ring or a prolapse-support pessary. Some people can insert and remove it themselves; others need help. Significant prolapse or altered vaginal anatomy can make retention difficult. Persistent discomfort, ulceration or a ring that cannot be removed needs clinical advice. Our pelvic organ prolapse guide explains support pessaries separately.
Check compatibility with condoms or diaphragms: some cream bases can weaken latex. Ask about your exact product and barrier method rather than relying on general advice about “water-based” or “hormonal” products. Vaginal estrogen itself does not provide contraception or protection from sexually transmitted infections.
Do you need progesterone with vaginal estrogen?
The answer depends on the actual preparation and regimen, and Canadian labels are not fully aligned with specialist guidance. Contemporary menopause and GSM guidance generally does not require routine added progestogen for recommended low-dose local vaginal estrogen. That advice cannot be extended to every amount of every vaginal cream, nor to systemic estrogen.
The Canadian monographs reviewed for Premarin cream, Estragyn and Estring explicitly advise progestin protection when the uterus is present. Vagifem’s low-dose regimen has different labeling; Imvexxy can be used with or without a uterus, but its Canadian label notes limitations in long-term study data. Estragyn’s broad labeled dose range should not simply be treated as interchangeable with a 10-microgram estradiol insert. Ask the prescriber to explain the product-specific evidence, whether the proposed schedule differs from the label, and why their plan is appropriate for you.
If you already take systemic estrogen, do not stop the progestogen prescribed to protect your uterine lining because a local-estrogen article says progesterone is “not needed.” Nor should a new leaflet warning prompt you to add somebody else’s progesterone. Resolve the difference with your prescriber or pharmacist. Unexpected bleeding needs evaluation whichever regimen you use.
Absorption, breast cancer and long-term use
Absorption into the bloodstream is generally low with recommended low-dose local products, but it is not zero and varies by formulation, dose and tissue condition. The risks of systemic HRT should not be presented as if they were proven to be identical for a low-dose vaginal insert. Equally, “local” is not a guarantee that all doses are suitable for every medical history. Tell the prescriber about cancer, unexplained bleeding, clotting history and all other hormone treatment.
After breast cancer, nonhormonal moisturizers and lubricants are usually considered first. If symptoms remain troublesome, current guidance allows discussion of low-dose vaginal estrogen through shared decision-making with the cancer team. This can differ from Canadian package contraindications and is especially important during aromatase-inhibitor treatment, where uncertainty about recurrence risk remains. Do not stop an aromatase inhibitor or tamoxifen to manage vaginal symptoms without the oncology team’s advice.
GSM often returns when treatment stops, so ongoing treatment may be appropriate after periodic review. Product labels have their own duration language: for example, the Estring patient information reviewed states a maximum recommended continuous duration of two years, while the cream labels emphasize short-term use. Specialist guidance may support longer individualized low-dose treatment. This difference deserves an explicit prescribing discussion rather than an unqualified “safe forever” claim. New symptoms and bleeding change the plan; routine scans or biopsies are not generally required solely because an asymptomatic person uses recommended low-dose local therapy.
What does it cost in Canada?
There is no reliable single Canadian retail price. A pharmacy quote includes the product, quantity, markup and dispensing arrangements; insurance eligibility and deductibles determine what you actually pay. An initial daily-treatment phase can cost more than maintenance. Ask for the full price of the prescribed pack, its expected duration and the price after your plan is applied.
For a transparent benchmark, the Ontario Drug Benefit formulary, checked November 6, 2026, lists drug-benefit unit prices of approximately $0.93 per gram for Premarin cream, $4.91 per Vagifem insert, $3.69 per Imvexxy insert and $106.54 per Estring ring. Thus eight maintenance inserts have ingredient benchmarks of about $39.25 for Vagifem or $29.55 for Imvexxy; a ring covers 90 days. These are public-plan ingredient benchmarks in Canadian dollars, not verified cash retail quotes or promises of coverage. They exclude pharmacy charges and do not price the loading phase. No comparable Ontario Estragyn price was established in this review.
Coverage is product-specific. In BC, the Plan NP list checked for this article includes Premarin vaginal cream and both Imvexxy strengths as full-benefit vaginal estrogen products; it does not list every product in our comparison. Ontario formulary inclusion likewise does not make everyone eligible for ODB. Private coverage must be checked against your own plan and DIN. A covered alternative may be worth discussing, but a pharmacist cannot assume that different hormones and schedules are equivalent.
What if the pharmacy cannot obtain it—or it does not help?
Estring still appears as marketed in Health Canada’s database; it should not be described as discontinued in Canada on the basis of an old shortage notice. That does not establish that your pharmacy has stock today. Official shortage information and wholesaler supply can change, and this review could not independently establish a complete live shortage status for every pack. Ask the pharmacy to check the exact DIN and current supply before you run out. See our Canadian shortage guide for the broader process.
Improvement takes time, and maintenance is usually different from the starting schedule. If benefit is incomplete after the agreed trial, check the diagnosis, application and actual regimen before escalating treatment. Moisturizers used regularly and lubricants used for friction may still help; they serve different purposes. Pelvic-floor pain, skin disease, infection and prolapse may need their own treatment. The best formulation is one you can use comfortably and consistently, with a clear follow-up plan—not necessarily the newest product or the highest dose.
Sources and product information
- Health Canada Drug Product Database: marketed status and DINs
- Vagifem 10 Canadian monograph
- Imvexxy Canadian monograph
- Estring Canadian monograph and patient information
- Premarin Vaginal Cream Canadian information (monograph revised April 2026)
- Estragyn manufacturer monograph
- NICE NG23: GSM, local estrogen and breast cancer
- AUA/SUFU/AUGS GSM guideline (2025)
- AUA/CUA/SUFU recurrent UTI guideline (amended 2025)
Canadian products, guidance and coverage checked November 6, 2026. Prices and supply can change. This is educational information, not an individual prescription.